Estimates of overall survival (IMAGE)

Sichuan International Medical Exchange and Promotion Association

Estimates of overall survival

Caption

The study revealed significant overall survival (OS) benefits with the combination of pyrotinib and fulvestrant for HR+/HER2+ metastatic breast cancer patients.  Notably, trastuzumab-resistant patients achieved an exceptional 3-year survival rate of 95.8% (95% CI: 88.2–100%).  Furthermore, patients receiving prior endocrine therapy had a 3-year survival rate of 89.8%, highlighting the potential of this combination therapy in extending survival for specific patient subgroups.

Credit

Ying Wang

Usage Restrictions

Please cite source

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.